Asia
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Savonix, a global leader in digital tests for cognitive health, and Bayer’s Consumer Health Division today announced a partnership agreement to work together to validate the effects of Bayer’s multivitamin supplement Berocca in the Malaysian market.
Todos Medical Ltd. announced it has entered into a binding term sheet with HWH World Pte Ltd., a wholly-owned subsidiary of Singapore eDevelopment for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada.
Eisai Co., Ltd. has announced that it received the 33rd “IIA Japan Chairman’s Award” of the Institute of Internal Auditors
Collaborating researchers at the University of Iowa and Capital Medical University in Beijing, China, found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.
Helsinn and Mundipharma China Pharmaceutical jointly announce that the National Medical Products Administration has approved the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting in China.
Agreement Extends Biocon’s Footprint to Greater China, the World’s 2nd Largest Pharma Market
The Data Safety Monitoring Board ran a safety review and recommended the trials end because of an unfavorable risk-benefit ratio.
Chinese researchers published a study in the New England Journal of Medicine describing their use of a form of gene therapy to treat an HIV-positive man.
PRESS RELEASES